PL2054050T3 - Leczenie zaburzeń chrząstki z zastosowaniem FGF-18 - Google Patents

Leczenie zaburzeń chrząstki z zastosowaniem FGF-18

Info

Publication number
PL2054050T3
PL2054050T3 PL07802876T PL07802876T PL2054050T3 PL 2054050 T3 PL2054050 T3 PL 2054050T3 PL 07802876 T PL07802876 T PL 07802876T PL 07802876 T PL07802876 T PL 07802876T PL 2054050 T3 PL2054050 T3 PL 2054050T3
Authority
PL
Poland
Prior art keywords
fgf
treatment
cartilage disorders
cartilage
disorders
Prior art date
Application number
PL07802876T
Other languages
English (en)
Inventor
Alberto Gimona
Christoph H Ladel
Baur Elmar Vom
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of PL2054050T3 publication Critical patent/PL2054050T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL07802876T 2006-08-25 2007-08-24 Leczenie zaburzeń chrząstki z zastosowaniem FGF-18 PL2054050T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06119557 2006-08-25
US84060006P 2006-08-28 2006-08-28
EP07802876A EP2054050B1 (en) 2006-08-25 2007-08-24 Treatment of cartilage disorders with fgf-18
PCT/EP2007/058830 WO2008023063A2 (en) 2006-08-25 2007-08-24 Treatment of cartilage disorders with fgf-18

Publications (1)

Publication Number Publication Date
PL2054050T3 true PL2054050T3 (pl) 2013-01-31

Family

ID=38984134

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07802876T PL2054050T3 (pl) 2006-08-25 2007-08-24 Leczenie zaburzeń chrząstki z zastosowaniem FGF-18

Country Status (14)

Country Link
US (1) US8207115B2 (pl)
EP (1) EP2054050B1 (pl)
JP (2) JP5815206B2 (pl)
KR (1) KR101419961B1 (pl)
AR (1) AR062522A1 (pl)
AU (1) AU2007287510B2 (pl)
CA (1) CA2658511C (pl)
CY (1) CY1113136T1 (pl)
EA (1) EA015644B1 (pl)
HR (1) HRP20120643T1 (pl)
IL (1) IL197169A (pl)
MX (1) MX2009002063A (pl)
PL (1) PL2054050T3 (pl)
WO (1) WO2008023063A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012038953A2 (en) 2010-09-21 2012-03-29 Hepacore Ltd. Fgf-18 truncated variants having increased receptor specificity and uses thereof
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
JP5918909B2 (ja) * 2012-06-25 2016-05-18 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 標的化治療薬
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
EP2880179B1 (en) * 2012-08-06 2017-12-13 Merck Patent GmbH Genetic markers for predicting responsiveness to fgf-18 compound
CN104755629A (zh) * 2012-08-06 2015-07-01 默克专利有限公司 软骨疾病的预后生物标记
RU2695343C2 (ru) * 2013-12-24 2019-07-23 Арес Трейдинг С.А. Состав fgf-18 в ксилоглюкановых гелях
MX2016010872A (es) * 2014-02-20 2016-11-17 Merck Patent Gmbh Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.
EP3107591B1 (en) * 2014-02-20 2018-04-18 Merck Patent GmbH Fgf-18 in graft transplantation and tissue engineering procedures
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
WO2016141250A1 (en) * 2015-03-03 2016-09-09 Radius Health, Inc. USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
AU2016256470B2 (en) 2015-04-29 2020-10-15 Radius Pharmaceuticals, Inc. Methods of treating cancer
EP3957654A1 (en) 2015-07-15 2022-02-23 Prosit Sole Biotechnology (Beijing) Co., Ltd Fusion polypeptides and methods of use
US20180236032A1 (en) * 2015-08-13 2018-08-23 Merck Patent Gmbh Combination composition comprising fgf-18 compound
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
LT3565542T (lt) 2017-01-05 2024-07-10 Radius Pharmaceuticals, Inc. Polimorfinės rad1901-2hcl formos
CN107338218B (zh) * 2017-07-28 2020-11-24 中国人民解放军总医院第一附属医院 一种诱导脂肪干细胞向软骨细胞分化的诱导分化培养基和方法
BR112020005035A2 (pt) 2017-09-21 2020-09-15 Merck Patent Gmbh proteína de fusão comprendendo porção fgf-18
SI3688468T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
CA3076029A1 (en) * 2017-09-29 2019-04-04 Merck Patent Gmbh Metabolic biomarkers for predicting responsiveness to fgf-18 compound
CN112423844B (zh) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
ES2980597T3 (es) 2018-09-10 2024-10-02 Merck Patent Gmbh Marcadores útiles en las estrategias de enriquecimiento para el tratamiento de la artrosis
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
EP3920959A1 (en) 2019-02-08 2021-12-15 Merck Patent GmbH Treatment of patients at risk of rapid progression of osteoarthritis
CN109836487B (zh) * 2019-03-01 2022-06-17 重庆派金生物科技有限公司 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用
CN117721115A (zh) * 2022-09-06 2024-03-19 深圳瑞吉生物科技有限公司 用于治疗骨关节炎的mRNA及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510209A (ja) 1994-03-08 1997-10-14 オステオサ インコーポレイテッド 骨の成長を刺激するための繊維芽細胞成長因子の用途
US20050043234A1 (en) 1996-10-16 2005-02-24 Deisher Theresa A. Novel FGF homologs
JPH11332570A (ja) * 1998-05-27 1999-12-07 Shionogi & Co Ltd 新規な線維芽細胞成長因子及びそれをコードする遺伝子
ATE539157T1 (de) * 1999-12-02 2012-01-15 Zymogenetics Inc Methoden welche auf zellen zielen, die die fibroblasten wachtumsfaktor-rezeptoren-3 oder -2 exprimieren
AU2002237124B2 (en) 2001-02-28 2008-03-06 Chondrogene Inc. Compositions and methods relating to osteoarthritis
ES2493840T3 (es) * 2002-10-07 2014-09-12 Zymogenetics, Inc. Procedimiento de administración de FGF-18
EP1896053B1 (en) * 2004-07-06 2018-10-31 ZymoGenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
US7858341B2 (en) * 2004-12-10 2010-12-28 Zymogenetics, Inc. FGF18 production in prokaryotic hosts

Also Published As

Publication number Publication date
HRP20120643T1 (hr) 2012-08-31
EA200970224A1 (ru) 2009-08-28
JP5815206B2 (ja) 2015-11-17
CA2658511C (en) 2019-02-19
IL197169A0 (en) 2009-12-24
WO2008023063A3 (en) 2008-05-02
CA2658511A1 (en) 2008-02-28
US8207115B2 (en) 2012-06-26
US20100016223A1 (en) 2010-01-21
KR101419961B1 (ko) 2014-07-30
JP2014088429A (ja) 2014-05-15
CY1113136T1 (el) 2016-04-13
JP2010501531A (ja) 2010-01-21
AR062522A1 (es) 2008-11-12
AU2007287510B2 (en) 2012-08-30
KR20090051100A (ko) 2009-05-20
EA015644B1 (ru) 2011-10-31
AU2007287510A1 (en) 2008-02-28
WO2008023063A2 (en) 2008-02-28
EP2054050A2 (en) 2009-05-06
EP2054050B1 (en) 2012-08-08
IL197169A (en) 2013-08-29
MX2009002063A (es) 2009-03-06

Similar Documents

Publication Publication Date Title
PL2054050T3 (pl) Leczenie zaburzeń chrząstki z zastosowaniem FGF-18
ZA200900426B (en) Treatment of cartilage disorders with FGF-18
EP1981526A4 (en) ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS
ZA200900734B (en) Combination treatment for metabolic disorders
IL230335A (en) A drug used to treat cartilage disease
IL194189A0 (en) Combination treatment of metabolic disorders
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
GB0703909D0 (en) Treatment of anxiety disorders
IL198488A0 (en) Treatment of pervasive developmental disorders
HK1247943A1 (zh) 發育相關疾病的治療
IL198196A0 (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
GB0619500D0 (en) Treatment of fibrosis
GB0607952D0 (en) Novel treatment
EP2037943A4 (en) TREATMENT OF BIND WEB DISEASES
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
GB0604460D0 (en) Treatment
GB0623740D0 (en) Treatment of disease
HK1145282A1 (en) Treatment of sleep disorders
GB0602857D0 (en) The treatment of sialorrhoea
ZA200902765B (en) Treatment of pulp
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0625602D0 (en) Treatment of sialorrhoea
GB0618705D0 (en) Treatment of joint disorders
GB0619218D0 (en) Treatment of conformational disorders
GB0602855D0 (en) The Treatment Of Sialorrhoea